banner
 
bar

program

slides
bar
 
 

Evolving Paradigms for
Optimizing Management of
Metastatic Breast Cancer

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium:

Internet-based program

Method of Physician Participation Utilized in Learning Process:

There are no fees for participating and receiving CME credit for this activity. During the period August 31, 2011 through August 31, 2013 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) register and complete the evaluation form; and 4) print out your CME certificate.

Estimated Time to Complete Educational Activity:

2.75 hours

Course Overview:

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in the management of metastatic breast cancer.

Release Date:

April 31, 2011

Expiration Date:

April 31, 2013

Intended Audience:

  • Oncologists
  • Oncology Pharmacists
  • Breast cancer specialists
  • Oncology surgeons
  • Women's health specialists
  • Internal medicine specialists
  • Hospitalists
  • Surgeons

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

EisaiSupported by an
Independent Educational Grant
from Eisai, Inc.

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and CMEducation Resources. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure:

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Program Faculty and Disclosures:

DEBU TRIPATHY, MD — Program Chair
Professor of Medicine
University of Southern California
USC University Hospital and Norris Cancer Hospital
Los Angeles, CA

No conflict of interest exists.

PARASKEVI GIANNAKAKOU, PhD
Associate Professor of Pharmacology in Medicine
Division of Hematology & Medical Oncology
Weill Cornell Medical College
New York, NY

Consultant: Eisai

SARA A. HURVITZ, MD
Assistant Clinical Professor of Medicine
Director Breast Oncology Program
UCLA
Division of Hematology & Oncology
Los Angeles, CA

No conflict of interest exists

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Jan Hixon, RN, BSN, MA, Trace Hutchison, PharmD, Julia Kimball, RN, BSN, Samantha Mattiucci, PharmD, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following CMEducation Resources planners and managers: Gideon Bosker and Milo Falcon,hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use:

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), CMEducation Resources and Eisai, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, CMEducation Resources and Eisai, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Educational Objectives:

Upon completion of this CME activity, the participants will be able to:

  1. Apply evidence-based strategies that may prolong survival in patients with metastatic breast cancer (MBC) who have received multiple, established chemotherapeutic treatment courses (i.e., heavily treated) with documented remissions
  2. Detail the safety, efficacy, and survival prolongation profiles associated with novel treatments being evaluated for MSB, including the role of nontaxane, microtubule dynamics inhibitors
  3. Review the tolerability factors, outcomes, and evidence-based rationale for the use of microtubule inhibitors in heavily pretreated women with metastatic breast cancer who had already received treatment with anthracycline and a taxane for MBC
  4. Discuss rationale, combination therapy, trial design, and outcome metrics focused on progression-free survival and overall survival in heavily treated patients with MBC
  5. Compare the tolerability, safety, and impact on clinical outcomes of late stage agents for MBC, focusing on comparative value of taxanes versus novel agents (microtubule inhibitors) when used as combination therapy with anthracyclines and similar settings
  6. Compare the side effect profiles of anti-tumor agents used for poorly responsive MBC, focusing on such adverse effects as alopecia and peripheral neuropathy
  7. List optimal approaches to sequencing chemotherapeutic agents for MBC—including anthracyclines, taxanes, capecitabine, and novel microtubule-inhibiting agents—to identify a sequencing strategy that achieves the optimal balance of survival benefits and side effect profiles
  8. Discuss which add-on agents in heavily treated patients with MBC are most effective in prolonging survival and maintaining end-of-live, quality-of-life (QoL)
  9. Compare the side effects of agents (taxanes, capecitabine) to hali-chondrin B-based inhibitors of microtubule dynamics, and how the mechanism of action that produce microtubule growth suppression can impact side effect profiles, overcome drug resistance observed with standard agents used for sequenced therapy, and prolong survival in MBC

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer:

Copyright © 2011 by CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, or the program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © 2011 Resources, LLC All rights reserved

 
6

 

Key Program Topics Include:

Anaphase
Antimitotic
Antitubulin
Baseline Characteristics
Bevacizumab
bisphosphonate
Breast Cancer
Palliation
CA163-048
Capecitabine
Centromere
chemotherapy
combination
cyclophosphamide
Denosumab
Docetaxel

Doxorubicin 6
Endocrine
Enhancers Induce Microtubule Bundles
Epothilones
Eribulin
Eribulin Mesylate
Everolimus
FAC
Gemcitabine
Halichondrin B
Hematotoxicity
Interphase
ixabepilone
ligand inhibitors

MDR
melphalan
Metaphase
Metastatic
Microtubule
mitomycin/5-FU
NCCN
agen
No Drug
Olaparib
paclitaxel
PARP Inhibitors
Pegylated lip. doxuribcin
physician's choice (Twelves, 2010 ASCO abstract)

Progression-free Survival
Bevacizumab
RANK
resistant HER2-pos disease
Taxane
Taxol
temozolomide
Trastuzumab
Tubulin Dimer
Tumor
Veliparib
Vinorelbine
zolendronic acid